

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listing of claims in the application.

LISTING OF CLAIMS:

1-52. (Cancelled).

53. (New) A method for stimulating an immune response in an individual, comprising providing a C-type lectin receptor on an antigen presenting cell of said individual with an antigen, said antigen comprising a glycoconjugate comprising a fucose residue or a glycoconjugate comprising at least one end standing N-acetylglucosamine or derivative or multimer thereof, wherein said antigen is provided with said fucose residue or said at least one end standing N-acetylglucosamine or derivative and/or multimer thereof.

54. (New) A method according to claim 53, wherein said C-type lectin receptor is DC-SIGN.

55. (New) A method according to claim 53, wherein said glycoconjugate comprising a fucose residue comprises Lewis bloodgroup antigen, Le^x, Le^y, Le^a, Le^b of LDNF or a C-type lectin binding part, derivative and/or analogue thereof.

56. (New) A method according to claim 53, wherein said antigen lacked a fucose residue or an end standing N-acetylglucosamine or derivative and/or multimer thereof, prior to providing said antigen therewith.

57. (New) A method according to claim 53, wherein said antigen is a tumor antigen or an antigen of a pathogen.

58. (New) A composition for stimulating an immune response in an individual, said composition comprising an antigen comprising a glycoconjugate comprising a fucose residue or a glycoconjugate comprising at least one end standing N-acetylglucosamine or derivative or multimer thereof, wherein said antigen is provided with said fucose residue or said at least one end standing N-acetylglucosamine or derivative and/or multimer thereof.

59. (New) A composition according to claim 58, wherein said glycoconjugate comprising a fucose residue comprises Lewis bloodgroup antigen Le^x, Le^y, Le^a, Le^b of LDNF or a C-type lectin binding part, derivative and/or analogue thereof.

60. (New) A composition according to claim 58, wherein said antigen lacked a fucose residue or an end standing N-acetylglucosamine or derivative and/or multimer thereof, prior to providing said antigen therewith.

61. (New) A composition according to claim 58, wherein said antigen is a tumor antigen or an antigen of a pathogen.

62. (New) A vaccine comprising a composition according to claim 58.

63. (New) A method for augmenting or inducing an effective immune response comprising providing an antigen presenting cell with a ligand comprising an antigen and a glycoconjugate comprising a fucose residue or a glycoconjugate comprising at least one end standing N-acetylglucosamine or a derivative or multimer thereof, wherein said antigen is provided with said fucose residue or said at least one end standing N-acetylglucosamine or derivative an/or multimer thereof.

64. (New) A method according to claim 53 for the treatment of an individual suffering from a cancer.

65. (New) A method according to claim 53 for enhancing immunity against a pathogen.

66. (New) A method according to claim 63 for the treatment of an individual suffering from a cancer.

67. (New) A method according to claim 63 for enhancing immunity against a pathogen.